Selective PI3K Deals Abound, But is Targeted Always Best?
While early efforts to target phosphoinositide-3 kinase (PI3K) involved pan-inhibition, biotechs like Intellikine Inc. and Calistoga Pharmaceuticals Inc. differentiated themselves by selectively targeting the alpha, beta, delta and/or gamma isoforms of PI3K rather than hitting the whole family.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Sign up for Perspectives FREE e-mail newsletter